LON:GSK - GlaxoSmithKline Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 1,510.40 +13.60 (+0.91 %)
(As of 05/22/2018 09:52 AM ET)
Previous CloseGBX 1,496.80
Today's RangeGBX 1,494.20 - GBX 1,528.95
52-Week RangeGBX 1,235.20 - GBX 1,724.50
Volume4.15 million shs
Average Volume9.12 million shs
Market Capitalization£65.63 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About GlaxoSmithKline (LON:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:GSK
CUSIPN/A
Phone+44-20-80475000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins9.36%
Return on Equity348.10%
Return on Assets4.98%

Miscellaneous

EmployeesN/A
Outstanding Shares4,920,000,000

GlaxoSmithKline (LON:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a dividend on Wednesday, April 25th. Shareholders of record on Thursday, May 10th will be given a dividend of GBX 19 per share on Thursday, July 12th. This represents a yield of 1.35%. The ex-dividend date is Thursday, May 10th. The official announcement can be viewed at this link. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline (LON:GSK) issued its quarterly earnings data on Wednesday, April, 25th. The company reported $24.60 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $24.30 by $0.30. GlaxoSmithKline had a net margin of 9.36% and a return on equity of 348.10%. View GlaxoSmithKline's Earnings History.

What price target have analysts set for GSK?

22 Wall Street analysts have issued 1 year price targets for GlaxoSmithKline's stock. Their predictions range from GBX 1,130 to GBX 2,030. On average, they anticipate GlaxoSmithKline's share price to reach GBX 1,538.57 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, Chief Exec. Officer & Director (Age 48)
  • Mr. Simon P. Dingemans, Chief Financial Officer & Exec. Director (Age 54)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 56)
  • Mr. Daniel E. Troy, Sr. VP and Gen. Counsel

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news stories about the company an impact score of 47.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of GlaxoSmithKline?

Shares of GSK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately GBX 1,508.80.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of £65.63 billion.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The company can be reached via phone at +44-20-80475000.


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  655 (Thanks for Voting!)
Underperform Votes:  1,294 (Thanks for Voting!)
Total Votes:  1,949
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (LON:GSK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for GlaxoSmithKline in the last 12 months. Their average twelve-month price target is GBX 1,538.57The high price target for GSK is GBX 2,030 and the low price target for GSK is GBX 1,130. There are currently 1 sell rating, 13 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.322.322.272.14
Ratings Breakdown: 1 Sell Rating(s)
13 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
13 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
12 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,538.57GBX 1,536.67GBX 1,522.14GBX 1,569.75

GlaxoSmithKline (LON:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/16/2018Liberum CapitalReiterated RatingBuyView Rating Details
5/14/2018Jefferies GroupSet Price TargetBuyGBX 1,650View Rating Details
4/27/2018Deutsche BankSet Price TargetNeutralGBX 1,420View Rating Details
4/26/2018UBSSet Price TargetBuyGBX 1,600View Rating Details
4/26/2018Kepler Capital MarketsSet Price TargetNeutralGBX 1,400View Rating Details
4/26/2018Credit Suisse GroupReiterated RatingNeutralGBX 1,450View Rating Details
4/25/2018Berenberg BankBoost Price TargetBuyGBX 1,780 ➝ GBX 1,790View Rating Details
4/23/2018BarclaysReiterated RatingOverweightGBX 1,650View Rating Details
4/3/2018Morgan StanleySet Price TargetNeutralGBX 1,400View Rating Details
3/28/2018HSBCReiterated RatingBuyGBX 2,030View Rating Details
3/23/2018JPMorgan ChaseReiterated RatingNeutralView Rating Details
3/23/2018Goldman SachsSet Price TargetBuyGBX 1,750View Rating Details
3/23/2018Shore CapitalReiterated RatingHoldView Rating Details
3/22/2018BNP ParibasReiterated RatingNeutralGBX 1,560View Rating Details
3/14/2018Societe GeneraleReiterated RatingSellGBX 1,130View Rating Details
2/8/2018Beaufort SecuritiesUpgradeBuyGBX 1,450 ➝ GBX 1,500View Rating Details
2/7/2018Sanford C. BernsteinSet Price TargetNeutralGBX 1,580View Rating Details
12/13/2017CitigroupReiterated RatingNeutralGBX 1,400View Rating Details
12/6/2017Bank of AmericaSet Price TargetNeutralGBX 1,450View Rating Details
11/6/2017InvestecDowngradeHoldGBX 1,800 ➝ GBX 1,390View Rating Details
10/26/2017S&P GlobalSet Price TargetNeutralGBX 1,500View Rating Details
9/19/2017Bryan, Garnier & CoReiterated RatingNeutralGBX 1,710View Rating Details
10/27/2016NatixisReiterated RatingNeutralGBX 1,750View Rating Details
8/4/2016Independent ResearchSet Price TargetNeutralGBX 1,800View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
(Data available from 5/22/2016 forward)

Earnings

GlaxoSmithKline (LON:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018Q1 2018GBX 24.30GBX 24.60ViewN/AView Earnings Details
10/25/2017Q3 2017GBX 31.80GBX 32.50GBX 784.30 billionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GlaxoSmithKline (LON:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2018GBX 191.35%5/10/20185/10/20187/12/2018
2/7/2018GBX 231.78%2/22/20182/22/20184/12/2018
10/25/2017GBX 191.41%11/9/201711/9/20171/11/2018
7/26/2017GBX 191.23%8/10/20178/10/201710/12/2017
4/26/2017GBX 191.21%5/11/20175/11/20177/13/2017
2/8/2017GBX 231.47%2/23/20172/23/20174/13/2017
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (LON GSK) Insider Trading and Institutional Ownership History

Insider Trading History for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON GSK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/25/2018Philip R HamptonInsiderBuy3,028GBX 1,445£43,754.60
4/11/2018Emma WalmsleyInsiderBuy8GBX 1,435£114.80
3/9/2018Dominic RedfernInsiderBuy10GBX 1,343£134.30
2/19/2018Patrick VallanceInsiderSell14,022GBX 1,318£184,809.96
2/16/2018Victoria WhyteInsiderSell4,544GBX 1,307£59,390.08
2/12/2018Victoria WhyteInsiderSell5,199GBX 1,295£67,327.05
2/9/2018Patrick VallanceInsiderBuy9GBX 1,298£116.82
2/7/2018Sir Roy AndersonInsiderBuy562GBX 1,278£7,182.36
1/10/2018Dominic RedfernInsiderBuy10GBX 1,333£133.30
12/18/2017Patrick VallanceInsiderSell20,000GBX 1,310£262,000
12/11/2017Dominic RedfernInsiderBuy9GBX 1,302£117.18
11/9/2017Patrick VallanceInsiderBuy10GBX 1,364£136.40
10/25/2017Urs RohnerInsiderBuy473GBX 1,518£7,180.14
10/12/2017Simon DingemansInsiderBuy1,076GBX 1,527£16,430.52
10/10/2017Victoria WhyteInsiderBuy9GBX 1,518£136.62
9/11/2017Dominic RedfernInsiderBuy8GBX 1,501£120.08
8/9/2017Dominic RedfernInsiderBuy8GBX 1,519£121.52
7/26/2017Manvinder Singh BangaInsiderBuy2,267GBX 1,599£36,249.33
7/14/2017Patrick VallanceInsiderBuy861GBX 1,618£13,930.98
7/11/2017Victoria WhyteInsiderBuy8GBX 1,604£128.32
6/20/2017Victoria WhyteInsiderSell4,820GBX 1,693£81,602.60
6/9/2017Simon DingemansInsiderBuy7GBX 1,701£119.07
5/10/2017Patrick VallanceInsiderBuy7GBX 1,615£113.05
4/26/2017Vivienne CoxInsiderBuy335GBX 1,583£5,303.05
4/18/2017Emma WalmsleyInsiderBuy83GBX 1,647£1,367.01
4/13/2017Dominic RedfernInsiderBuy230GBX 1,639£3,769.70
3/9/2017Sir Andrew P WittyInsiderBuy7GBX 1,673£117.11
3/7/2017Moncef SlaouiInsiderBuy56GBX 2,072£1,160.32
2/22/2017Simon DingemansInsiderSell3,589GBX 1,640£58,859.60
2/20/2017Sir Andrew P WittyInsiderSell10,633GBX 1,634£173,743.22
2/16/2017Patrick VallanceInsiderSell32,996GBX 1,624£535,855.04
2/9/2017Victoria WhyteInsiderSell4,820GBX 1,576£75,963.20
2/8/2017Vivienne CoxInsiderBuy342GBX 1,555£5,318.10
1/11/2017Simon DingemansInsiderBuy8GBX 1,596£127.68
1/9/2017Moncef SlaouiInsiderBuy58GBX 1,972£1,143.76
12/9/2016Sir Andrew P WittyInsiderBuy8GBX 1,478£118.24
11/9/2016Victoria WhyteInsiderBuy8GBX 1,593£127.44
11/3/2016Moncef SlaouiInsiderBuy6GBX 1,937£116.22
10/27/2016Sir Andrew P WittyInsiderSell10,000GBX 1,636£163,600
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (LON GSK) News Headlines

Source:
DateHeadline
BRIEF-GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For JulucaBRIEF-GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For Juluca
www.reuters.com - May 21 at 8:23 AM
BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction ...BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction ...
www.reuters.com - May 21 at 8:23 AM
EU approves GlaxoSmithKline JVs Juluca HIV drugEU approves GlaxoSmithKline JV's Juluca HIV drug
www.marketwatch.com - May 21 at 8:23 AM
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIVViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV
finance.yahoo.com - May 21 at 8:23 AM
GlaxoSmithKlines (GSK) Buy Rating Reiterated at Liberum CapitalGlaxoSmithKline's (GSK) Buy Rating Reiterated at Liberum Capital
www.americanbankingnews.com - May 16 at 3:41 PM
Jefferies Group Reiterates "GBX 1,650" Price Target for GlaxoSmithKline (GSK)Jefferies Group Reiterates "GBX 1,650" Price Target for GlaxoSmithKline (GSK)
www.americanbankingnews.com - May 14 at 10:39 AM
BRIEF-GlaxoSmithKline CFO Simon Dingemans To Retire From CompanyBRIEF-GlaxoSmithKline CFO Simon Dingemans To Retire From Company
www.reuters.com - May 9 at 8:27 AM
GlaxoSmithKline CFO to retire in May 2019GlaxoSmithKline CFO to retire in May 2019
www.marketwatch.com - May 9 at 8:27 AM
Adaptimmune Reports First Quarter 2018 Financial Results and Business UpdateAdaptimmune Reports First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 9 at 8:27 AM
Drugmaker GSK rings in more change as CFO heads for exit in 2019Drugmaker GSK rings in more change as CFO heads for exit in 2019
finance.yahoo.com - May 9 at 8:27 AM
Glaxos Advair Is the $100 Billion Asthma Drug That Wont DieGlaxo's Advair Is the $100 Billion Asthma Drug That Won't Die
finance.yahoo.com - May 4 at 8:24 AM
UPS hires former pharmaceutical exec as VP of healthcare logistics strategyUPS hires former pharmaceutical exec as VP of healthcare logistics strategy
www.bizjournals.com - May 2 at 8:28 AM
GlaxoSmithKline (GSK) Receives Average Recommendation of "Hold" from BrokeragesGlaxoSmithKline (GSK) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 30 at 5:38 AM
GlaxoSmithKline Q1 2018: Still Too Many UncertaintiesGlaxoSmithKline Q1 2018: Still Too Many Uncertainties
seekingalpha.com - April 29 at 6:33 PM
Deutsche Bank Reiterates "GBX 1,420" Price Target for GlaxoSmithKline (GSK)Deutsche Bank Reiterates "GBX 1,420" Price Target for GlaxoSmithKline (GSK)
www.americanbankingnews.com - April 27 at 12:44 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 26Form 6-K GLAXOSMITHKLINE PLC For: Apr 26
www.streetinsider.com - April 27 at 8:38 AM
BRIEF-GlaxoSmithKline Consumer Nigeria Says Q1 Ended March Group Profit Before Tax 369 Million NairaBRIEF-GlaxoSmithKline Consumer Nigeria Says Q1 Ended March Group Profit Before Tax 369 Million Naira
www.reuters.com - April 27 at 8:38 AM
GlaxoSmithKline (GSK) Releases  Earnings Results, Beats Expectations By $0.30 EPSGlaxoSmithKline (GSK) Releases Earnings Results, Beats Expectations By $0.30 EPS
www.americanbankingnews.com - April 26 at 3:36 PM
GlaxoSmithKline (GSK) Insider Acquires £43,754.60 in StockGlaxoSmithKline (GSK) Insider Acquires £43,754.60 in Stock
www.americanbankingnews.com - April 26 at 1:34 PM
GlaxoSmithKline (GSK) PT Set at GBX 1,400 by Kepler Capital MarketsGlaxoSmithKline (GSK) PT Set at GBX 1,400 by Kepler Capital Markets
www.americanbankingnews.com - April 26 at 12:27 PM
UBS Reiterates GBX 1,600 Price Target for GlaxoSmithKline (GSK)UBS Reiterates GBX 1,600 Price Target for GlaxoSmithKline (GSK)
www.americanbankingnews.com - April 26 at 12:27 PM
GlaxoSmithKline (GSK) Announces Dividend of GBX 19GlaxoSmithKline (GSK) Announces Dividend of GBX 19
www.americanbankingnews.com - April 26 at 11:40 AM
GlaxoSmithKline (GSK) Receives Neutral Rating from Credit Suisse GroupGlaxoSmithKline (GSK) Receives Neutral Rating from Credit Suisse Group
www.americanbankingnews.com - April 26 at 10:08 AM
GlaxoSmithKlines (GSK) "Hold" Rating Reaffirmed at Deutsche BankGlaxoSmithKline's (GSK) "Hold" Rating Reaffirmed at Deutsche Bank
www.americanbankingnews.com - April 26 at 10:08 AM
GlaxoSmithKline (GSK) Given a GBX 1,780 Price Target by Berenberg Bank AnalystsGlaxoSmithKline (GSK) Given a GBX 1,780 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - April 25 at 11:30 AM
HPV Vaccine Market 2022 Demand, Key Players- Merck and Co., GlaxoSmithKlineHPV Vaccine Market 2022 Demand, Key Players- Merck and Co., GlaxoSmithKline
www.prnewswire.com - April 25 at 8:26 AM
GlaxoSmithKline profit and revenue fallGlaxoSmithKline profit and revenue fall
www.marketwatch.com - April 25 at 8:26 AM
Currency weighs on GlaxoSmithKline Q1 sales and earningsCurrency weighs on GlaxoSmithKline Q1 sales and earnings
finance.yahoo.com - April 25 at 8:26 AM
GSK rules out entering Shire takeover battleGSK rules out entering Shire takeover battle
finance.yahoo.com - April 25 at 8:26 AM
[$$] Stronger pound hinders GlaxoSmithKline[$$] Stronger pound hinders GlaxoSmithKline
finance.yahoo.com - April 25 at 8:26 AM
Currency weighs on GlaxoSmithKline first-quarter sales and earningsCurrency weighs on GlaxoSmithKline first-quarter sales and earnings
finance.yahoo.com - April 25 at 8:26 AM
Glaxo (GSK) Misses on both Earnings and Revenue in Q1Glaxo (GSK) Misses on both Earnings and Revenue in Q1
finance.yahoo.com - April 25 at 8:26 AM
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
finance.yahoo.com - April 25 at 8:26 AM
GlaxoSmithKline Stock Dips After Missing Q1 ForecastsGlaxoSmithKline Stock Dips After Missing Q1 Forecasts
finance.yahoo.com - April 25 at 8:26 AM
New shingles vaccine shines as currency hits GSK earningsNew shingles vaccine shines as currency hits GSK earnings
finance.yahoo.com - April 25 at 8:26 AM
Global CNS Market Analysis 2018 With AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson & Pfizer Leading ...Global CNS Market Analysis 2018 With AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson & Pfizer Leading ...
www.businesswire.com - April 24 at 8:25 AM
Barclays Reaffirms Overweight Rating for GlaxoSmithKline (GSK)Barclays Reaffirms Overweight Rating for GlaxoSmithKline (GSK)
www.americanbankingnews.com - April 23 at 6:30 AM
GlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by UBS AnalystsGlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by UBS Analysts
www.americanbankingnews.com - April 20 at 10:18 PM
Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
finance.yahoo.com - April 20 at 8:33 AM
GlaxoSmithKline (GSK) Stock Rating Lowered by CitigroupGlaxoSmithKline (GSK) Stock Rating Lowered by Citigroup
www.americanbankingnews.com - April 19 at 9:09 PM
GlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD PatientsGlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD Patients
www.nasdaq.com - April 19 at 8:23 AM
Experts query case for GlaxoSmithKlines new 3-in-1 lung drugExperts query case for GlaxoSmithKline's new 3-in-1 lung drug
finance.yahoo.com - April 18 at 5:39 PM
Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPDLandmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD
finance.yahoo.com - April 18 at 5:39 PM
GlaxoSmithKlines (GSK) Buy Rating Reiterated at Jefferies GroupGlaxoSmithKline's (GSK) Buy Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 18 at 4:44 PM
GlaxoSmithKline, Innoviva Says IMPACT Study Shows Benefits Of Trelegy ElliptaGlaxoSmithKline, Innoviva Says IMPACT Study Shows Benefits Of Trelegy Ellipta
www.nasdaq.com - April 18 at 8:24 AM
GlaxoSmithKlines (GSK) Equal weight Rating Reiterated at Morgan StanleyGlaxoSmithKline's (GSK) Equal weight Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - April 17 at 7:34 PM
Biotech Analysis Central Pharma News: GlaxoSmithKline Passes Along Pipeline, Pulse Impresses, Celldexs FailureBiotech Analysis Central Pharma News: GlaxoSmithKline Passes Along Pipeline, Pulse Impresses, Celldex's Failure
seekingalpha.com - April 17 at 8:41 AM
GlaxoSmithKline (GSK) Rating Reiterated by Deutsche BankGlaxoSmithKline (GSK) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - April 17 at 12:40 AM
GlaxoSmithKline (GSK) Rating Reiterated by JPMorgan ChaseGlaxoSmithKline (GSK) Rating Reiterated by JPMorgan Chase
www.americanbankingnews.com - April 16 at 9:48 PM
GlaxoSmithKline (GSK) Earns Hold Rating from Deutsche BankGlaxoSmithKline (GSK) Earns Hold Rating from Deutsche Bank
www.americanbankingnews.com - April 16 at 4:16 PM

SEC Filings

GlaxoSmithKline (LON:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

GlaxoSmithKline (LON GSK) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.